Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Income from Continuing Operations (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Income from Continuing Operations data on record, last reported at 5730000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 75.91% year-over-year to 5730000.0; the TTM value through Dec 2025 reached 23363000.0, up 73.43%, while the annual FY2025 figure was 23363000.0, 73.43% up from the prior year.
  • Income from Continuing Operations reached 5730000.0 in Q4 2025 per MIRM's latest filing, down from 2905000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 57280000.0 in Q4 2021 and bottomed at 74038000.0 in Q2 2023.
  • Average Income from Continuing Operations over 5 years is 24731950.0, with a median of 26100500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 253.97% in 2021, then crashed 175.01% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 57280000.0 in 2021, then tumbled by 163.6% to 36431000.0 in 2022, then increased by 2.12% to 35659000.0 in 2023, then surged by 33.28% to 23790000.0 in 2024, then soared by 75.91% to 5730000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 5730000.0 in Q4 2025, 2905000.0 in Q3 2025, and 5861000.0 in Q2 2025.